# FDA recall D-0102-2024

> **Pfizer Inc.** · Class I · drug recall initiated 2023-10-02.

## Product

2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11

## Reason for recall

Presence of Particulate Matter: identified as glass.

## Distribution

Nationwide in the US and Puerto Rico.  The products were not distributed to government accounts or foreign consignees.

## Key facts

- **Recall number:** D-0102-2024
- **Recalling firm:** Pfizer Inc.
- **Classification:** Class I
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2023-10-02
- **Report date:** 2023-11-15
- **Termination date:** 2025-02-14

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** New York, NY, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0102-2024

## Citation

> AI Analytics. FDA recall D-0102-2024. Retrieved 2026-06-03 from https://api.ai-analytics.org/recall/D-0102-2024. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*